Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]
Combination of | |
---|---|
Celecoxib | Nonsteroidal anti-inflammatory drug (NSAID) |
Tramadol hydrochloride | Opioid agonist |
Clinical data | |
Trade names | Seglentis |
Other names | E-58425 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
|
Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]